Simon Chivers
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.
Journal: Molecular cancer therapeutics
Published: August 04, 2023
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
Journal: Molecular cancer therapeutics
Published: August 24, 2021
CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Journal: Journal for immunotherapy of cancer
Published: June 24, 2020
Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine.
Journal: Scientific reports
Published: January 10, 2018
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Journal: Blood
Published: October 26, 2017
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Journal: Molecular cancer therapeutics
Published: October 10, 2017
Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.
Journal: Regulatory toxicology and pharmacology : RTP
Published: August 20, 2016
Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?
Journal: Calcified tissue international
Published: November 03, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026